Dendritic cell-based immunotherapy

Immunotherapy using dendritic cell （DC）-based vaccination is an approved approach for harnessing the potential of a patient＇s own immune system to eliminate tumor cells in metastatic hormone-refractory cancer. Overall, al- though many DC vaccines have been tested in the clinic and proven to be immun...

Full description

Saved in:
Bibliographic Details
Published inCell research Vol. 27; no. 1; pp. 74 - 95
Main Authors Sabado, Rachel L, Balan, Sreekumar, Bhardwaj, Nina
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group UK 01.01.2017
Nature Publishing Group
Subjects
631/250/2504/133
631/250/251/1567
631/250/580
692/699/67/589/466
Animals
Antigen Presentation - immunology
Antigens, Neoplasm - immunology
Biomedical and Life Sciences
Cell Biology
Dendritic Cells - cytology
Dendritic Cells - immunology
Humans
Immune system
Immunity
Immunotherapy
Life Sciences
Review
Vaccination
Vaccines
临床试验
免疫原性
免疫治疗
免疫系统
树突状细胞
肿瘤免疫
肿瘤细胞
dendritic cell
immunotherapy
Online AccessGet full text

Cover

More Information
Summary:Immunotherapy using dendritic cell （DC）-based vaccination is an approved approach for harnessing the potential of a patient＇s own immune system to eliminate tumor cells in metastatic hormone-refractory cancer. Overall, al- though many DC vaccines have been tested in the clinic and proven to be immunogenic, and in some cases associated with clinical outcome, there remains no consensus on how to manufacture DC vaccines. In this review we will discuss what has been learned thus far about human DC biology from clinical studies, and how current approaches to apply DC vaccines in the clinic could be improved to enhance anti-tumor immunity.
Bibliography:dendritic cell; immunotherapy
31-1568
Immunotherapy using dendritic cell （DC）-based vaccination is an approved approach for harnessing the potential of a patient＇s own immune system to eliminate tumor cells in metastatic hormone-refractory cancer. Overall, al- though many DC vaccines have been tested in the clinic and proven to be immunogenic, and in some cases associated with clinical outcome, there remains no consensus on how to manufacture DC vaccines. In this review we will discuss what has been learned thus far about human DC biology from clinical studies, and how current approaches to apply DC vaccines in the clinic could be improved to enhance anti-tumor immunity.
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ISSN:1001-0602
1748-7838
1748-7838
DOI:10.1038/cr.2016.157